Vaxart, Inc. (VXRT) Scorecard
- 2026-Q2: Total return Lose; Revenue growth Win; EPS growth Lose.
- 2026-Q1: Total return Win; Revenue growth Win; EPS growth Lose.
- 2025-Q4: Total return Lose; Revenue growth Win; EPS growth Lose.
- 2025-Q3: Total return Lose; Revenue growth Win; EPS growth Lose.
35/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 5 wins, 7 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q21/3 |
LoseVXRT / S&P 0.00% / 15.20% |
WinVXRT / S&P 201.10% / 15.00% |
LoseVXRT / S&P VXRT unavailable / 50.40% |
| 2026-Q12/3 |
WinVXRT / S&P 74.29% / -4.33% |
WinVXRT / S&P 439.32% / 11.30% |
LoseVXRT / S&P VXRT unavailable / 27.70% |
| 2025-Q41/3 |
LoseVXRT / S&P -2.78% / 2.65% |
WinVXRT / S&P 726.68% / 9.00% |
LoseVXRT / S&P VXRT unavailable / 13.40% |
| 2025-Q31/3 |
LoseVXRT / S&P -20.00% / 8.12% |
WinVXRT / S&P 784.27% / 4.61% |
LoseVXRT / S&P VXRT unavailable / 13.45% |
| 2025-Q21/3 |
LoseVXRT / S&P 9.76% / 10.94% |
WinVXRT / S&P 479.58% / 4.83% |
LoseVXRT / S&P VXRT unavailable / 10.63% |
| 2025-Q11/3 |
LoseVXRT / S&P -37.88% / -4.27% |
WinVXRT / S&P 433.43% / 4.98% |
LoseVXRT / S&P VXRT unavailable / 10.57% |
| 2024-Q41/3 |
LoseVXRT / S&P -22.35% / 2.41% |
WinVXRT / S&P 288.94% / 5.25% |
LoseVXRT / S&P VXRT unavailable / 6.15% |
| 2024-Q32/3 |
WinVXRT / S&P 26.87% / 5.89% |
WinVXRT / S&P 303.27% / 5.89% |
LoseVXRT / S&P VXRT unavailable / 6.11% |
| 2024-Q21/3 |
LoseVXRT / S&P -48.46% / 4.28% |
WinVXRT / S&P 577.76% / 5.38% |
LoseVXRT / S&P VXRT unavailable / 5.12% |
| 2024-Q12/3 |
WinVXRT / S&P 128.07% / 10.56% |
WinVXRT / S&P 1174.75% / 5.71% |
LoseVXRT / S&P VXRT unavailable / 5.59% |
| 2023-Q41/3 |
LoseVXRT / S&P -24.00% / 11.69% |
WinVXRT / S&P 6796.26% / 6.81% |
LoseVXRT / S&P VXRT unavailable / 7.78% |
| 2023-Q32/3 |
WinVXRT / S&P 2.74% / -3.27% |
WinVXRT / S&P 2513.84% / 7.52% |
LoseVXRT / S&P VXRT unavailable / -5.03% |
| 2023-Q21/3 |
LoseVXRT / S&P -3.95% / 8.74% |
WinVXRT / S&P 472.42% / 9.50% |
LoseVXRT / S&P VXRT unavailable / -8.57% |
| 2023-Q11/3 |
LoseVXRT / S&P -20.83% / 7.50% |
WinVXRT / S&P 47.98% / 10.77% |
LoseVXRT / S&P VXRT unavailable / -15.69% |
| 2022-Q40/3 |
LoseVXRT / S&P -55.96% / 7.56% |
LoseVXRT / S&P -88.00% / 11.88% |
LoseVXRT / S&P VXRT unavailable / -17.99% |
| 2022-Q30/3 |
LoseVXRT / S&P -37.71% / -4.88% |
LoseVXRT / S&P -86.46% / 13.47% |
LoseVXRT / S&P VXRT unavailable / -1.41% |
| 2022-Q20/3 |
LoseVXRT / S&P -30.56% / -16.10% |
LoseVXRT / S&P -71.03% / 13.71% |
LoseVXRT / S&P VXRT unavailable / 11.04% |
| 2022-Q10/3 |
LoseVXRT / S&P -19.62% / -4.60% |
LoseVXRT / S&P -71.45% / 15.97% |
LoseVXRT / S&P VXRT unavailable / 42.23% |
| 2021-Q40/3 |
LoseVXRT / S&P -21.13% / 11.03% |
LoseVXRT / S&P -77.95% / 15.00% |
LoseVXRT / S&P VXRT unavailable / 96.40% |
| 2021-Q31/3 |
WinVXRT / S&P 6.14% / 0.58% |
LoseVXRT / S&P -84.56% / 10.77% |
LoseVXRT / S&P VXRT unavailable / 69.42% |
| 2021-Q21/3 |
WinVXRT / S&P 23.80% / 8.55% |
LoseVXRT / S&P -84.11% / 6.58% |
LoseVXRT / S&P VXRT unavailable / 51.81% |
| 2021-Q10/3 |
LoseVXRT / S&P 5.95% / 6.17% |
LoseVXRT / S&P -77.57% / -1.06% |
LoseVXRT / S&P VXRT unavailable / 7.39% |
| 2020-Q40/3 |
LoseVXRT / S&P -14.14% / 12.15% |
LoseVXRT / S&P -58.97% / -3.72% |
LoseVXRT / S&P VXRT unavailable / -33.42% |
| 2020-Q31/3 |
LoseVXRT / S&P -24.86% / 8.93% |
WinVXRT / S&P -1.39% / -2.04% |
LoseVXRT / S&P VXRT unavailable / -27.10% |
| 2020-Q22/3 |
WinVXRT / S&P 400.00% / 20.54% |
WinVXRT / S&P 3.38% / -0.46% |
LoseVXRT / S&P VXRT unavailable / -27.11% |
| 2020-Q11/3 |
WinVXRT / S&P 405.71% / -19.60% |
LoseVXRT / S&P -8.76% / 3.47% |
LoseVXRT / S&P VXRT unavailable / -14.75% |
| 2019-Q41/3 |
LoseVXRT / S&P -2.78% / 9.07% |
WinVXRT / S&P 137.12% / 5.36% |
LoseVXRT / S&P VXRT unavailable / 2.99% |
| 2019-Q31/3 |
LoseVXRT / S&P -46.27% / 1.70% |
WinVXRT / S&P 144.70% / 5.02% |
LoseVXRT / S&P VXRT unavailable / 0.21% |
| 2019-Q21/3 |
LoseVXRT / S&P -65.46% / 4.30% |
WinVXRT / S&P 99.15% / 6.64% |
LoseVXRT / S&P VXRT unavailable / 8.65% |
| 2019-Q11/3 |
LoseVXRT / S&P 3.19% / 13.65% |
WinVXRT / S&P 60.23% / 8.12% |
LoseVXRT / S&P VXRT unavailable / 14.29% |
| 2018-Q40/3 |
LoseVXRT / S&P -34.04% / -13.52% |
LoseVXRT / S&P -28.77% / 9.05% |
LoseVXRT / S&P VXRT unavailable / 18.23% |
| 2018-Q30/3 |
LoseVXRT / S&P -5.94% / 7.71% |
LoseVXRT / S&P -64.50% / 10.21% |
LoseVXRT / S&P VXRT unavailable / 19.06% |
| 2018-Q20/3 |
LoseVXRT / S&P -42.94% / 3.43% |
LoseVXRT / S&P -53.05% / 9.03% |
LoseVXRT / S&P VXRT unavailable / 14.46% |
| 2018-Q10/3 |
LoseVXRT / S&P -15.31% / -0.76% |
LoseVXRT / S&P -25.01% / 7.68% |
LoseVXRT / S&P -100.41% / 12.46% |
| 2017-Q41/3 |
LoseVXRT / S&P -17.39% / 6.64% |
LoseVXRT / S&P -39.80% / 7.03% |
WinVXRT / S&P 3097.56% / 13.82% |
| 2017-Q32/3 |
LoseVXRT / S&P 2.99% / 4.48% |
WinVXRT / S&P 16.83% / 5.68% |
WinVXRT / S&P 3416.00% / 17.57% |
| 2017-Q21/3 |
LoseVXRT / S&P 3.08% / 3.09% |
LoseVXRT / S&P -12.35% / 4.83% |
WinVXRT / S&P 3913.64% / 17.74% |
| 2017-Q11/3 |
LoseVXRT / S&P -47.15% / 6.07% |
LoseVXRT / S&P -47.58% / 3.67% |
WinVXRT / S&P 2450.00% / 13.32% |
| 2016-Q40/3 |
LoseVXRT / S&P -35.94% / 3.82% |
LoseVXRT / S&P -27.61% / 2.09% |
LoseVXRT / S&P -5.75% / 7.05% |
| 2016-Q32/3 |
WinVXRT / S&P 37.14% / 3.85% |
LoseVXRT / S&P -70.31% / 0.20% |
WinVXRT / S&P 47.06% / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | VXRT total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 28.21% | 20.78% |
| Annualized return | 28.21% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | VXRT total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -94.44% | 83.14% |
| Annualized return | -43.89% | 12.86% |
10Y · 2016-09-01 to 2026-08-27
| Metric | VXRT total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -96.58% | 319.30% |
| Annualized return | -28.65% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B |